Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PRALATREXATE Cause Malignant neoplasm progression? 107 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 107 reports of Malignant neoplasm progression have been filed in association with PRALATREXATE (Pralatrexate). This represents 23.0% of all adverse event reports for PRALATREXATE.

107
Reports of Malignant neoplasm progression with PRALATREXATE
23.0%
of all PRALATREXATE reports
37
Deaths
12
Hospitalizations

How Dangerous Is Malignant neoplasm progression From PRALATREXATE?

Of the 107 reports, 37 (34.6%) resulted in death, 12 (11.2%) required hospitalization, and 9 (8.4%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PRALATREXATE. However, 107 reports have been filed with the FAERS database.

What Other Side Effects Does PRALATREXATE Cause?

Stomatitis (93) Platelet count decreased (56) Disease progression (46) Neutrophil count decreased (40) Anaemia (39) Pyrexia (38) Mucosal inflammation (37) Drug ineffective (32) Off label use (30) Death (26)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which PRALATREXATE Alternatives Have Lower Malignant neoplasm progression Risk?

PRALATREXATE vs PRALSETINIB PRALATREXATE vs PRAMIPEXOLE PRALATREXATE vs PRAMIPEXOLE\PRAMIPEXOLE PRALATREXATE vs PRAMLINTIDE PRALATREXATE vs PRASTERONE

Related Pages

PRALATREXATE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression PRALATREXATE Demographics